Cargando…

The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity

Dysfunctional visceral adipose tissue (VAT) in obesity is associated with type 2 diabetes (DM) but underlying mechanisms remain unclear. Our objective in this discovery analysis was to identify genes and proteins regulated by DM to elucidate aberrant cellular metabolic and signaling mediators. We pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Carruthers, Nicholas J., Strieder-Barboza, Clarissa, Caruso, Joseph A., Flesher, Carmen G., Baker, Nicki A., Kerk, Samuel A., Ky, Alexander, Ehlers, Anne P., Varban, Oliver A., Lyssiotis, Costas A., Lumeng, Carey N., Stemmer, Paul M., O’Rourke, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405693/
https://www.ncbi.nlm.nih.gov/pubmed/34462518
http://dx.doi.org/10.1038/s41598-021-96995-0
_version_ 1783746380417728512
author Carruthers, Nicholas J.
Strieder-Barboza, Clarissa
Caruso, Joseph A.
Flesher, Carmen G.
Baker, Nicki A.
Kerk, Samuel A.
Ky, Alexander
Ehlers, Anne P.
Varban, Oliver A.
Lyssiotis, Costas A.
Lumeng, Carey N.
Stemmer, Paul M.
O’Rourke, Robert W.
author_facet Carruthers, Nicholas J.
Strieder-Barboza, Clarissa
Caruso, Joseph A.
Flesher, Carmen G.
Baker, Nicki A.
Kerk, Samuel A.
Ky, Alexander
Ehlers, Anne P.
Varban, Oliver A.
Lyssiotis, Costas A.
Lumeng, Carey N.
Stemmer, Paul M.
O’Rourke, Robert W.
author_sort Carruthers, Nicholas J.
collection PubMed
description Dysfunctional visceral adipose tissue (VAT) in obesity is associated with type 2 diabetes (DM) but underlying mechanisms remain unclear. Our objective in this discovery analysis was to identify genes and proteins regulated by DM to elucidate aberrant cellular metabolic and signaling mediators. We performed label-free proteomics and RNA-sequencing analysis of VAT from female bariatric surgery subjects with DM and without DM (NDM). We quantified 1965 protein groups, 23 proteins, and 372 genes that were differently abundant in DM vs. NDM VAT. Proteins downregulated in DM were related to fatty acid synthesis and mitochondrial function (fatty acid synthase, FASN; dihydrolipoyl dehydrogenase, mitochondrial, E3 component, DLD; succinate dehydrogenase-α, SDHA) while proteins upregulated in DM were associated with innate immunity and transcriptional regulation (vitronectin, VTN; endothelial protein C receptor, EPCR; signal transducer and activator of transcription 5B, STAT5B). Transcriptome indicated defects in innate inflammation, lipid metabolism, and extracellular matrix (ECM) function, and components of complement classical and alternative cascades. The VAT proteome and transcriptome shared 13 biological processes impacted by DM, related to complement activation, cell proliferation and migration, ECM organization, lipid metabolism, and gluconeogenesis. Our data revealed a marked effect of DM in downregulating FASN. We also demonstrate enrichment of complement factor B (CFB), coagulation factor XIII A chain (F13A1), thrombospondin 1 (THBS1), and integrins at mRNA and protein levels, albeit with lower q-values and lack of Western blot or PCR confirmation. Our findings suggest putative mechanisms of VAT dysfunction in DM.
format Online
Article
Text
id pubmed-8405693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84056932021-09-01 The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity Carruthers, Nicholas J. Strieder-Barboza, Clarissa Caruso, Joseph A. Flesher, Carmen G. Baker, Nicki A. Kerk, Samuel A. Ky, Alexander Ehlers, Anne P. Varban, Oliver A. Lyssiotis, Costas A. Lumeng, Carey N. Stemmer, Paul M. O’Rourke, Robert W. Sci Rep Article Dysfunctional visceral adipose tissue (VAT) in obesity is associated with type 2 diabetes (DM) but underlying mechanisms remain unclear. Our objective in this discovery analysis was to identify genes and proteins regulated by DM to elucidate aberrant cellular metabolic and signaling mediators. We performed label-free proteomics and RNA-sequencing analysis of VAT from female bariatric surgery subjects with DM and without DM (NDM). We quantified 1965 protein groups, 23 proteins, and 372 genes that were differently abundant in DM vs. NDM VAT. Proteins downregulated in DM were related to fatty acid synthesis and mitochondrial function (fatty acid synthase, FASN; dihydrolipoyl dehydrogenase, mitochondrial, E3 component, DLD; succinate dehydrogenase-α, SDHA) while proteins upregulated in DM were associated with innate immunity and transcriptional regulation (vitronectin, VTN; endothelial protein C receptor, EPCR; signal transducer and activator of transcription 5B, STAT5B). Transcriptome indicated defects in innate inflammation, lipid metabolism, and extracellular matrix (ECM) function, and components of complement classical and alternative cascades. The VAT proteome and transcriptome shared 13 biological processes impacted by DM, related to complement activation, cell proliferation and migration, ECM organization, lipid metabolism, and gluconeogenesis. Our data revealed a marked effect of DM in downregulating FASN. We also demonstrate enrichment of complement factor B (CFB), coagulation factor XIII A chain (F13A1), thrombospondin 1 (THBS1), and integrins at mRNA and protein levels, albeit with lower q-values and lack of Western blot or PCR confirmation. Our findings suggest putative mechanisms of VAT dysfunction in DM. Nature Publishing Group UK 2021-08-30 /pmc/articles/PMC8405693/ /pubmed/34462518 http://dx.doi.org/10.1038/s41598-021-96995-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Carruthers, Nicholas J.
Strieder-Barboza, Clarissa
Caruso, Joseph A.
Flesher, Carmen G.
Baker, Nicki A.
Kerk, Samuel A.
Ky, Alexander
Ehlers, Anne P.
Varban, Oliver A.
Lyssiotis, Costas A.
Lumeng, Carey N.
Stemmer, Paul M.
O’Rourke, Robert W.
The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
title The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
title_full The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
title_fullStr The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
title_full_unstemmed The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
title_short The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
title_sort human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405693/
https://www.ncbi.nlm.nih.gov/pubmed/34462518
http://dx.doi.org/10.1038/s41598-021-96995-0
work_keys_str_mv AT carruthersnicholasj thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT striederbarbozaclarissa thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT carusojosepha thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT fleshercarmeng thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT bakernickia thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT kerksamuela thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT kyalexander thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT ehlersannep thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT varbanolivera thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT lyssiotiscostasa thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT lumengcareyn thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT stemmerpaulm thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT orourkerobertw thehumantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT carruthersnicholasj humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT striederbarbozaclarissa humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT carusojosepha humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT fleshercarmeng humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT bakernickia humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT kerksamuela humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT kyalexander humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT ehlersannep humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT varbanolivera humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT lyssiotiscostasa humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT lumengcareyn humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT stemmerpaulm humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity
AT orourkerobertw humantype2diabetesspecificvisceraladiposetissueproteomeandtranscriptomeinobesity